NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · IEX Real-Time Price · USD
3.190
+0.015 (0.47%)
Apr 23, 2024, 9:30 AM EDT - Market open

Company Description

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.

It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.

The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.

The company was founded in 2011 and is headquartered in Carmel, Indiana.

NeurAxis, Inc.
NeurAxis logo
Country United States
Founded 2011
IPO Date Aug 9, 2023
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Brian Carrico

Contact Details

Address:
11611 N. Meridian St, Suite 330
Carmel, Indiana 46032
United States
Phone (812) 689-0791
Website neuraxis.com

Stock Details

Ticker Symbol NRXS
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001933567
ISIN Number US64134X2018
Employer ID 45-5079684
SIC Code 3845

Key Executives

Name Position
Brian Carrico President, Chief Executive Officer and Director
Dr. Adrian Miranda Senior Vice President of Science and Technology and Chief Medical Officer
Thomas Carrico Chief Regulatory Officer and Director
Dr. Christopher Robin Brown D.D.S. Founder, Director of Innovation and Director
Gary Peterson Founder, Director of Design and Engineering and Director
Timothy Robert Henrichs Chief Financial Officer
Dan Clarence Chief Operating Officer and Director

Latest SEC Filings

Date Type Title
Apr 16, 2024 10-K Annual Report
Apr 16, 2024 8-K Current Report
Apr 9, 2024 8-K Current Report
Apr 1, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 28, 2024 8-K Current Report
Mar 11, 2024 8-K Current Report
Feb 15, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 8-K Current Report
Dec 26, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals